What is the cash burn rate and runway given upcoming trial expenses and potential PhaseâŻ3 studies?
Answer
The press release you referenced â Edgewise Therapeuticsâ Q2âŻ2025 earnings announcement â highlights a number of scientific milestones (positive topâline data from the MESA extension trial in Becker muscular dystrophy, encouraging results from the PhaseâŻ2 LYNX and FOX trials in Duchenne muscular dystrophy, etc.) but it does not disclose the companyâs cashâburn rate, its remaining cash runway, or specific cost estimates for upcoming trial activities or any anticipated PhaseâŻ3 programs.
Therefore, based on the information that was made available in this particular news release, we cannot provide a quantitative answer to the question about:
- Cashâburn rate (e.g., dollars per month or quarter)
- Cash runway (how many months or years of operating cash the company has left)
- Projected trialârelated expenses for future studies
- Potential PhaseâŻ3 study funding needs
What to do next
If you need those financial details, they are typically found in one of the following sources:
| Source | What youâll find |
|---|---|
| Form 10âQ (Quarterly Report) filed with the SEC | Detailed breakdown of cash, cash equivalents, operating expenses, and âcash burnâ for the quarter; discussion of forwardâlooking cash needs and runway. |
| Form 8âK (Current Report) â Press Release Attachment | The full press release may include a âFinancial Highlightsâ table that lists cash on hand and burn rate. |
| Investor Presentation / Earnings Call Transcript | Management often discusses cash runway in the âLiquidity & Capital Resourcesâ slide and may provide guidance on upcoming trial spend. |
| Companyâs Investor Relations website | Frequently updated slide decks or PDFs that summarize cash position and forecasted expense categories. |
When you locate the relevant filings or investor materials, look for the following line items to calculate the runway yourself:
- Cash and cash equivalents (including any marketable securities).
- Total operating expenses (or specifically âR&D expenseâ) for the most recent period.
- Projected quarterly or monthly cash burn (often disclosed as âCash used in operating activitiesâ).
- Management commentary on upcoming milestones (e.g., âWe anticipate additional cash requirements of $X million to fund PhaseâŻ3 initiation in FY2026â).
Simple runway calculation (if you obtain the numbers):
[
\text{Runway (months)} = \frac{\text{Cash on hand}}{\text{Average monthly cash burn}}
]
or, if burn is presented quarterly:
[
\text{Runway (quarters)} = \frac{\text{Cash on hand}}{\text{Quarterly cash burn}}
]
Adjust the calculation for any known inflows (e.g., expected financing, partnership payments) or outflows (e.g., anticipated PhaseâŻ3 trial spend, milestone payments).
Bottom line
- The current press release does not supply the cashâburn rate or runway figures.
- To obtain those metrics, consult Edgewise Therapeuticsâ most recent SEC filings (FormâŻ10âQ/8âK) or the full investorâpresentation accompanying the earnings release.